Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

• Status: Recruiting
• Trial end date: 2024-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Deferoxamine

Criteria

Inclusion Criteria:

• Has measurable metastatic triple-negative breast cancer, with at least 1 measurable lesion per RECIST criteria.

• Fail second-line or above anti-tumor treatment

• Evaluation is stable disease with a trend of progression.

• Minimum life expectancy 16 weeks

• Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis

• ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks

• Normal organ function.

• Has signed a Patient Informed Consent Form.

Exclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) score of ≥ 2

• Patients with severe liver and kidney insufficiency

• Deferoxamine Ingredients allergy

• With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment

• Inability or unwillingness to comply with study procedures, including inability to take regular oral medication

• Researchers consider it is not suitable for participation.